Alpine Immune Sciences, Inc., a development-stage specialty pharmaceutical company, engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. It is developing ALPN-101, an ICOS/CD28 antagonist program for the treatment of inflammatory diseases. The company is based in Seattle, Washington.